Cefimed

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefimed

Cefimed is a prescription-only medicine that functions as an anti-infective agent for systemic use, with its identity centered on the active component, Cefixime.

Property Description
Active ingredient Cefixime (Cefixime trihydrate)
Form Tablets, Capsules, Granules for Oral Suspension
Pharmacological class Third-Generation Cephalosporin Antibiotic
Common use Treatment of bacterial infections
Origin Semi-synthetic β-Lactam compound

What Type of Medicine is Cefimed?

Cefimed is classified as a semi-synthetic antibiotic belonging to the third-generation cephalosporin group, which makes it an advanced anti-infective agent. The core active ingredient, Cefixime, is chemically defined by a β-Lactam structure typical of this class. This pharmacological classification grants it a broad-spectrum of activity, meaning it can target and eliminate a wide array of different bacteria. Third-generation cephalosporins are recognized in clinical practice for their increased stability against bacterial enzymes compared to earlier classes, making them particularly useful in scenarios such as uncomplicated infections of the urinary or respiratory tracts.

Composition and Available Forms

The medicine is a single-ingredient product, containing only Cefixime trihydrate as the therapeutic compound. Cefimed is formulated exclusively for oral administration, providing a non-invasive route of use suitable for various patient groups. This includes multiple dosage forms: conventional tablets, capsules, and granules for oral suspension which is reconstituted into a liquid. The availability of the oral suspension form is a distinctive feature of Cefixime preparations, ensuring flexible dosing options for both pediatric patients (children) and adults who may have difficulty swallowing solid oral forms.

Cefimed's General Therapeutic Purpose

Cefimed's general purpose is to resolve illness by acting as a bactericidal agent against established bacterial infections caused by susceptible organisms. The mechanism is defined by its ability to interfere with bacterial integrity: Cefixime works by killing the bacteria, a process achieved by inhibiting the synthesis of the bacterial cell wall. Cefixime is utilized as an oral option in managing common bacterial threats, such as those causing infections of the ear, throat, or lower urinary tract.

Regulatory References

  1. Third-Generation Cephalosporins (NIH StatPearls)

What side effects are possible with Cefimed?

Possible Side Effects and Safety Information

The safety profile of Cefimed (Cefixime) is structured by governmental regulatory agencies based on incidence and physiological impact. The most commonly reported adverse reactions are concentrated within the Gastrointestinal System, primarily including diarrhea and nausea, with diarrhea often being the most frequent event observed in clinical studies. Other common reactions may include loose stools, abdominal pain, and dyspepsia.


System-Organ Classes and Serious Reactions

Adverse effects listed in official labeling span multiple System-Organ Classes, including the Hemic and Lymphatic System, Hepatic (liver), Renal and Urinary Disorders, and the Central Nervous System.

Serious adverse reactions, though infrequent, are explicitly documented. These include severe Hypersensitivity Reactions such as anaphylaxis, life-threatening Severe Cutaneous Adverse Reactions (SCARS), and severe gastrointestinal issues like Clostridioides difficile-associated diarrhea (CDAD) or Pseudomembranous Colitis. Regulatory data also note the potential for Acute Renal Failure and rare neurological events like seizures or encephalopathy.


Safety Considerations for Specific Populations

Official regulatory documents contain specific safety constraints. For patients with significant renal impairment (Creatinine Clearance less than 60 mL/min), a dose adjustment is required. Furthermore, the efficacy and safety of Cefimed have not been established in infants under six months of age. Regulatory guidance also notes a documented risk of cross-hypersensitivity in patients with a known penicillin allergy and the need for caution when co-administered with anticoagulants, due to an officially documented potential for increased prothrombin time.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cefimed overdose centers on the potential for intensified adverse effects, particularly involving the nervous and gastrointestinal systems.

Overdose Presentation Severe Outcomes
Gastrointestinal Disturbances (Nausea, Vomiting, Diarrhea) Convulsions (Seizures)
Central Nervous System (CNS) Excitation Encephalopathy (Brain Dysfunction)

In cases of overexposure, patients with impaired renal function are noted to have an increased risk of severity due to reduced drug clearance leading to high systemic concentrations. The potential for seizures is explicitly documented in this patient group.

Required Emergency Actions

It is a regulatory mandate that immediate medical attention must be sought for any suspected Cefimed overdose, even in the absence of obvious symptoms. Urgent help from emergency services is required if severe manifestations occur, such as the onset of a seizure, collapse, or trouble breathing.

Management Statements

Management of Cefimed overdose is universally described as symptomatic and supportive treatment. No specific antidote is known to reverse the effects of Cefixime toxicity. Procedural steps such as gastric lavage or the administration of anticonvulsant therapy may be indicated, based on the clinical presentation and official protocol.

Therapeutic Uses of Cefimed

What Cefimed Treats: Main Uses and Benefits

Cefimed is commonly used to help manage the acute symptomatic distress of bacterial infections affecting the respiratory tract, the middle ear, and the urinary system. It is relevant for addressing conditions such as Otitis Media, Pharyngitis, Tonsillitis, and Uncomplicated Urinary Tract Infections (UTIs). It is also applied in managing Acute Exacerbations of Chronic Bronchitis when symptoms may intensify temporarily.

This antibiotic is generally applied in contexts where additional symptomatic support is needed to address symptoms related to inflammatory states and heightened physiological activity. It is used for managing symptom clusters that may become intense or disruptive, such as severe sore throat, painful swallowing, ear discomfort, and Dysuria (painful urination). The primary therapeutic benefit provides support that helps ease the overall symptom burden, and may assist with maintaining functional stability during episodes of acute bacterial infection.

Quick Fact: Relief for Acute Symptom Burden Cefimed is commonly used to help with conditions characterized by periods of heightened symptoms, supporting patients during difficult symptomatic episodes by easing distress.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Cefimed (cefixime) is generally used to treat bacterial infections in adults and children six months of age and older. Like all medications, it is not suitable for everyone, and certain conditions require careful consideration by a healthcare professional.

Who Should NOT Use Cefimed? (Contraindications)

Cefimed is contraindicated (should not be used) in patients with a known:

  • Allergy to Cefixime or any other cephalosporin antibiotic (e.g., Cefazolin, Cephalexin).
  • History of a severe, immediate allergic reaction (e.g., anaphylaxis) to penicillin antibiotics, due to the risk of cross-hypersensitivity.

Special Populations and Precautions

Caution and possible dose adjustment are necessary for patients with certain pre-existing medical conditions:

Patient Population Precautionary Note
Kidney impairment (Renal Disease) Dose adjustment is necessary as the drug is mainly cleared by the kidneys.
Gastrointestinal disease (e.g., Colitis) Use with caution, as cephalosporins can cause Clostridium difficile-associated diarrhea.
Bleeding problems or on anticoagulants Caution is advised, as Cefimed may be associated with a fall in prothrombin activity.
Phenylketonuria (PKU) The chewable tablet formulation may contain phenylalanine.

For pregnant or breastfeeding women, the drug should only be used if clearly needed, and nursing mothers may be advised to temporarily discontinue breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefimed (Cefixime) interacts with certain medicinal products, products, and diagnostic tests, requiring specific monitoring or precautionary measures as documented in regulatory labeling.


Documented Drug-Drug Interactions

Interacting Substance/Class Documented Effect and Action Constraint Classification
Anticoagulants (e.g., Warfarin) Enhanced anticoagulant effect, leading to prolonged Prothrombin Time (INR). Requires Monitoring
Probenecid Increases Cefixime blood concentrations (AUC/Cmax) and decreases its renal clearance. Requires Monitoring
Carbamazepine Reports of elevated Carbamazepine plasma levels upon co-administration. Requires Monitoring
Live, Attenuated Vaccines (e.g., Cholera Vaccine) May diminish the therapeutic efficacy of the vaccine. Contraindicated Combination

Other Interactions

  • Food: While overall absorption is not significantly reduced, taking Cefimed with food may prolong the time it takes to reach maximum concentration in the blood.
  • Hormonal Contraceptives: Use of Cefixime may decrease the efficacy of combined oral contraceptives.
  • Laboratory Tests: Cefixime can cause false-positive results for glucose in urine using copper reduction tests (e.g., Benedict's solution, Clinitest) but not with glucose-oxidase tests (e.g., TesTape, Clinistix).

Population Considerations

Patients with impaired renal function are noted as being at increased risk for alterations in prothrombin activity when Cefixime is co-administered with anticoagulants, necessitating close monitoring.

Mechanism of Action

How Cefimed Works

Targeting Penicillin-Binding Proteins

Cefimed, a cephalosporin, works by covalently binding to and inhibiting penicillin-binding proteins (PBPs), a class of bacterial transpeptidases located within the cell wall. This irreversible binding permanently inactivates the enzymes responsible for the final stages of cell wall assembly.

Disruption of Peptidoglycan Synthesis

Inhibition of PBPs prevents the terminal transpeptidation reaction essential for cross-linking the peptidoglycan strands, which are the fundamental structural components of the bacterial cell wall. As new components cannot be properly incorporated, the structural integrity of the cell wall is immediately compromised.

Mechanistic Cascade and Cell Lysis

This structural failure results in severe osmotic instability within the bacterial cell. The resultant pressure imbalance leads to the degradation of the cell membrane and intracellular contents, culminating in bacterial cell lysis against sensitive strains.

Dosage and Administration Information

How to Use Cefimed

Cefimed (Cefixime) administration is strictly by the oral route, with no other methods approved in official labeling. The medicine is available in several forms, including capsules, tablets, and granules for oral suspension.


Standard Dosing and Frequency

The standard adult usage pattern specifies a total daily dose of 400 mg. This amount is administered either as a single 400 mg dose once daily (QD) or as two divided doses of 200 mg every 12 hours. Treatment duration typically ranges from 7 to 14 days, although infections caused by Streptococcus pyogenes generally require a course of at least 10 days to fulfill the therapeutic requirement.


Administration Conditions

Cefimed may be taken with or without food, as its absorption is not significantly affected by meals. The oral suspension form must be thoroughly shaken before each dose is measured and administered. If a 400 mg tablet is scored, it may be split to facilitate the 200 mg twice-daily regimen. However, certain dosage forms, such as tablets or capsules, should not be substituted for the oral suspension when managing specific conditions like otitis media.


Population-Specific Dosing

Specific dosage adjustments are mandated for patients with impaired kidney function. Adult patients whose estimated creatinine clearance is less than 60 mL/min require dose modification. For severely impaired renal function (CrCl le 20 mL/min), the dose is typically limited to 200 mg once daily. Pediatric patients (over six months old) are administered a daily dose based on body weight, commonly 8 mg/kg per day.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefimed


Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

Research on Cefimed (Cefixime) for uncomplicated urinary tract infections (UTIs) focused on the measurement of bacterial clearance associated with its use. Studies conducted for this purpose include Randomized Controlled Trials (RCTs), and Cefimed was evaluated in trials that included other treatments for comparison. Findings from these trials describe patterns observed in the studies related to measurements of bacteriological eradication, which refers to whether laboratory tests reported the absence of the specific bacteria causing the UTI. This body of evidence is relied upon by regulators for this clinical context. Despite this established use, long-term outcomes are not fully established regarding the durability of these findings, and limited information is available on recurrence rates.


Evidence for Use in Acute Otitis Media (AOM) and Respiratory Tract Infections

Cefimed was studied for the management of infections affecting the middle ear and respiratory tract, such as in conditions involving periods of heightened symptoms. Research examined outcomes related to outcomes describing episodic or acute changes in patient health. The studies mainly consisted of RCTs designed to evaluate Cefimed against other commonly prescribed oral antibiotics. Findings from these trials describe patterns observed in the studies related to measurements of bacteriological eradication. Due to the availability of an oral suspension form, research examined use in children with AOM, where studies explored short-term symptom changes. Data for long-term health outcomes following treatment are still emerging.


Evidence for Use in Uncomplicated Gonococcal Infections

The research mainly consists of Systematic Reviews and Meta-analyses that have compared Cefimed regimens against other antibiotic regimens. The focus of this research was primarily on microbiological cure. Findings from these studies have historically contributed to the broader evidence landscape by reporting microbiological cure rates in the studied populations, though findings were mixed when compared to certain other established treatments. A key limitation is that comparative evidence is lacking in large-scale current RCTs, and certainty remains low for the long-term effectiveness of any oral agent due to rapidly evolving resistance.


Research Gaps and Uncertainty

The primary research gaps stem from the need to continually monitor and track the evolution of bacterial resistance. Furthermore, follow-up durations were limited in many pivotal trials, meaning research exploring the truly long-term effects are not fully established. Finally, evidence quality varies across studies, and many regulatory summaries point to the necessity of ongoing surveillance and comparative research to assess the existing evidence base within the evolving treatment landscape. The research provides context but not individual predictions.

Key Studies & References

  1. WHO Essential Medicines List (EML) Cefixime entry and recommendations for Gonococcal infection
  2. Efficacy of Cefixime in The Treatment of Urinary Tract Infection (Study summarizing efficacy in UTI)

Frequently Asked Questions (FAQ)

Common questions about Cefimed (FAQ)


Q: How quickly does Cefimed usually start working?

Official product information describes that the medicine is absorbed after an oral dose, and it reaches its peak concentration in the bloodstream approximately four hours after administration. This peak concentration refers to when the drug reaches its highest level in the blood, although the overall duration of the treatment course is determined by your healthcare provider.


Q: What should I do if I miss a dose of Cefimed?

Official guidance describes that the dose is typically taken as soon as it is remembered. However, if it is already nearly time for the next scheduled dose, the regulatory instruction is to skip the missed dose. The instruction is to avoid taking two doses together to make up for a single missed dose.


Q: Does Cefimed interact with common pain relievers like ibuprofen?

The official drug label lists specific substances and drug classes, such as anticoagulants and carbamazepine, that require caution or monitoring due to documented interactions. Common over-the-counter pain relievers like ibuprofen are generally not explicitly named in the official interaction warnings.


Q: Are there any common supplements that should be avoided with Cefimed?

Regulatory documents prioritize detailing known interactions with other prescription medications. Since official warnings focus on known drug-drug interactions (e.g., blood thinners), they do not provide an exhaustive list of common dietary or herbal supplements, and no broad class warning is issued for general supplements.


Q: What happens if you take Cefimed for longer than prescribed?

The official documents note that taking higher amounts of the medicine, particularly in patients with kidney problems, may increase the risk of neurological events like seizures. In cases of acute, accidental overdose, regulatory information suggests that certain supportive measures, such as gastric lavage (stomach pumping), may be considered.


Q: Is Cefimed ever used for preventative purposes?

Official labeling emphasizes that the medicine should be used only to treat infections that are confirmed or strongly suspected to be caused by susceptible bacteria. This caution is noted to help reduce the development of drug resistance in bacteria.


Q: How does the FDA classify Cefimed for use in pregnancy?

Historically, the FDA assigned this medicine to Pregnancy Category B. This classification indicates that while animal reproduction studies have generally not demonstrated a risk to the fetus, there are no adequate and well-controlled studies specifically performed in pregnant women.


Q: Does Cefimed interact with antacids?

Official labeling lists specific interacting drugs and drug classes (such as anticoagulants), but antacids are not explicitly named in the official interaction warnings or contraindications. It is important to follow the guidance provided on the overall administration of the medicine.


Q: Can Cefimed cause yeast infections?

Candidiasis is listed in official documents as one of the documented adverse reactions. Candidiasis is the medical term for an infection caused by a fungus, which commonly presents as a yeast infection, particularly in the mouth or genital area.


Q: Can Cefimed interact with alcohol?

The official regulatory documents detailing the drug’s interactions do not list alcohol as a substance with a known, mandatory interaction warning or contraindication for this medicine.


Q: Are there specific food restrictions while taking Cefimed?

Official labeling states that the medicine may be administered without regard to food, meaning it can be taken with a meal or on an empty stomach. The labeling does not list any mandatory food restrictions or required dietary changes that must be followed during treatment.


Q: Is Cefimed the same as penicillin?

No, Cefimed is classified as a third-generation cephalosporin antibiotic, which is a different class of medicine from penicillin. However, official documents note a potential for cross-hypersensitivity between the two types of anti-infective agents.


Q: Can Cefimed cause dizziness or lightheadedness?

Dizziness is officially documented as one of the Central Nervous System adverse reactions reported with the use of this medicine. Other officially listed reactions in this category include headaches and seizures.


Q: Does the time of day matter when taking Cefimed?

Official dosing instructions define the required frequency, such as taking the dose once daily (QD) or twice daily (BID). However, they do not typically mandate a specific time of day (such as morning or night) for administration.


Q: Does Cefimed affect blood sugar levels?

Official labeling documents an interference with certain laboratory tests. Specifically, the medicine can cause a false-positive result for glucose in the urine when tested with older copper reduction methods, and official labeling focuses on an interference with the test result rather than an effect on blood sugar levels.


Q: How does Cefimed work differently from older medicines in its class?

Cefimed is classified as a third-generation cephalosporin. Official descriptions of this class indicate that it is recognized for its increased stability against certain bacterial enzymes compared to earlier generations of cephalosporins.


Q: Is Cefimed linked to any long-term side effects?

Regulatory reviews note that it is noted that the follow-up durations in many pivotal trials were limited, meaning research exploring the truly long-term effects is not fully established.

How should Cefimed be stored and disposed of?

How to Store and Dispose of Cefimed?

Proper storage and disposal of Cefimed (cefixime) are essential to maintain drug effectiveness and ensure safety, based on official regulatory requirements.

Formulation Storage Conditions Stability/Handling
Tablets/Capsules Store at controlled room temperature (20 C to 25 C), protected from moisture. Keep in the original container. Do not freeze.
Oral Suspension (Reconstituted) Must be stored in a refrigerator (2 C to 8 C). Shake well before each use. Discard after 14 days. Do not freeze.

All forms of Cefimed must be kept out of the reach of children. Unused or expired medication should be disposed of according to official guidelines, such as through a drug take-back program. Do not flush the medication down the toilet unless explicitly instructed to do so by local health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefimed found in:

A-Z Index: